Last updated on June 2017

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian Fallopian Tube or Primary Peritoneal Cancer Patients

Brief description of study

The purpose of this study is to determine how patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib versus chemotherapy.

Detailed Study Description

Rucaparib is an orally available, small molecule inhibitor of poly-adenosine diphosphate [ADP] ribose polymerase (PARP) being developed for treatment of ovarian cancer associated with homologous recombination (HR) DNA repair deficiency (HRD). The safety and efficacy of rucaparib has been evaluated in several Phase 1 and Phase 2 studies. An oral formulation is the focus of current development efforts. Rucaparib is currently being investigated as monotherapy in patients with cancer associated with breast cancer susceptibility gene 1 (BRCA1) or BRCA2 mutations. While PARP inhibitors have demonstrated consistent robust clinical activity in patients with relapsed ovarian cancer associated with HRD, prospective studies evaluating efficacy and safety of PARPi versus standard of care chemotherapy have been limited. The primary purpose of this Phase 3 study is to compare the efficacy and safety of rucaparib versus chemotherapy as treatment for relapsed ovarian cancer in patients with a deleterious BRCA1/2 mutation in their tumor.

Clinical Study Identifier: NCT02855944


Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Janiel Cragun, MD

The University of Arizona Cancer Center
Tucson, AZ United States
  Connect »

Krishnansu Tewari, MD

University of California Irvine Health Chao Family Comprehensive Cancer Center
Long Beach, CA United States
  Connect »

Laura Stampleman, MD

Pacific Cancer Care
Monterey, CA United States
  Connect »

Ling Ma, MD

Rocky Mountain Cancer Center
Denver, CO United States
  Connect »

Robert Holloway, MD

Florida Hospital Cancer Institute
Orlando, FL United States
  Connect »